Xueqiong Wu

List of Publications by Year in descending order

34 papers	592 citations	758635 12 h-index	676716 22 g-index
35 all docs	35 docs citations	35 times ranked	516 citing authors

#	Article	IF	Citations
1	SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies. International Reviews of Immunology, 2023, 42, 393-414.	1.5	26
2	Tuberculosis vaccine BCG: the magical effect of the old vaccine in the fight against the COVID-19 pandemic. International Reviews of Immunology, 2022, 41, 283-296.	1.5	29
3	A peptide-based vaccine ACP derived from antigens of Mycobacterium tuberculosis induced Th1 response but failed to enhance the protective efficacy of BCG in mice. Indian Journal of Tuberculosis, 2022, 69, 482-495.	0.3	13
4	Peptide-Based Vaccines for Tuberculosis. Frontiers in Immunology, 2022, 13, 830497.	2.2	37
5	Advances in Key Drug Target Identification and New Drug Development for Tuberculosis. BioMed Research International, 2022, 2022, 1-23.	0.9	10
6	Is the tuberculosis vaccine BCG an alternative weapon for developing countries to defeat COVID-19?. Indian Journal of Tuberculosis, 2021, 68, 401-404.	0.3	13
7	Peptides-Based Vaccine MP3RT Induced Protective Immunity Against Mycobacterium Tuberculosis Infection in a Humanized Mouse Model. Frontiers in Immunology, 2021, 12, 666290.	2.2	32
8	Prediction and analyses of HLAâ€Ⅱ restricted Mycobacterium tuberculosis CD4 + T cell epitopes in the Chinese population. Biotechnology and Applied Biochemistry, 2021, , .	1.4	2
9	COVID-19 pandemic: SARS-CoV-2 specific vaccines and challenges, protection via BCG trained immunity, and clinical trials. Expert Review of Vaccines, 2021, 20, 857-880.	2.0	32
10	Chinese Traditional Medicine NiuBeiXiaoHe (NBXH) Extracts Have the Function of Antituberculosis and Immune Recovery in BALB/c Mice. Journal of Immunology Research, 2021, 2021, 1-20.	0.9	3
11	Differential Diagnosis of Latent Tuberculosis Infection and Active Tuberculosis: A Key to a Successful Tuberculosis Control Strategy. Frontiers in Microbiology, 2021, 12, 745592.	1.5	60
12	Animal Models of Tuberculosis Vaccine Research: An Important Component in the Fight against Tuberculosis. BioMed Research International, 2020, 2020, 1-21.	0.9	28
13	Comparison of Three Cellular Immunoassays to Detect Tuberculosis Infection in 876 Healthy Recruits. Journal of Interferon and Cytokine Research, 2019, 39, 547-553.	0.5	0
14	Immunogenicity and Therapeutic Effects of Latency-Associated Genes in a Mycobacterium Tuberculosis Reactivation Mouse Model. Human Gene Therapy Methods, 2019, 30, 60-69.	2.1	11
15	The current status, challenges, and future developments of new tuberculosis vaccines. Human Vaccines and Immunotherapeutics, 2018, 14, 1697-1716.	1.4	81
16	Immunotherapeutic effects of Mycobacterium tuberculosis rv3407 DNA vaccine in mice. Autoimmunity, 2018, 51, 417-422.	1.2	8
17	Novel epitopes identified from Mycobacterium tuberculosis antigen Rv2629induces cytotoxic T lymphocyte response. Immunology Letters, 2018, 203, 21-28.	1.1	3
18	Immunogenicity and therapeutic effects of a Mycobacterium tuberculosis rv2190c DNA vaccine in mice. BMC Immunology, 2017, 18, 11.	0.9	13

#	Article	IF	Citations
19	Therapeutic effects of traditional Chinese medicine Niubeixiaohe in mouse tuberculosis models. Journal of Ethnopharmacology, 2017, 195, 318-323.	2.0	9
20	A new method of screening for latent tuberculosis infection: Results from army recruits in Beijing in 2014. Immunology Letters, 2017, 186, 28-32.	1.1	5
21	Immunogenicity and therapeutic effects of recombinant Ag85AB fusion protein vaccines in mice infected with Mycobacterium tuberculosis. Vaccine, 2017, 35, 3995-4001.	1.7	5
22	An alert of <i>Mycobacterium tuberculosis</i> infection of rhesus macaques in a wild zoo in China. Experimental Animals, 2017, 66, 357-365.	0.7	7
23	Immunogenicity and Therapeutic Effects of pVAX1-rv1419 DNA from Mycobacterium tuberculosis. Current Gene Therapy, 2016, 16, 249-255.	0.9	10
24	Ag85A/ESAT-6 chimeric DNA vaccine induces an adverse response in tuberculosis-infected mice. Molecular Medicine Reports, 2016, 14, 1146-1152.	1.1	10
25	Development of efflux pump inhibitors in antituberculosis therapy. International Journal of Antimicrobial Agents, 2016, 47, 421-429.	1.1	41
26	Evaluation of a wholeâ€blood chemiluminescent immunoassay of <scp>IFN</scp>â€Î³, <scp>IP</scp>â€10, and <scp>MCP</scp>â€1 for diagnosis of active pulmonary tuberculosis and tuberculous pleurisy patients. Apmis, 2016, 124, 856-864.	0.9	9
27	Association of Mannose-binding Lectin Polymorphisms with Tuberculosis Susceptibility among Chinese. Scientific Reports, 2016, 6, 36488.	1.6	12
28	Immunogenicity and therapeutic effects of pVAX1- rv1419 DNA from Mycobacterium tuberculosis. Current Gene Therapy, 2016, , .	0.9	4
29	Role of calcium channels in cellular antituberculosis effects: Potential of voltage-gated calcium-channel blockers inÂtuberculosis therapy. Journal of Microbiology, Immunology and Infection, 2015, 48, 471-476.	1.5	15
30	Polymorphisms in the Interleukin 18 Receptor 1 Gene and Tuberculosis Susceptibility among Chinese. PLoS ONE, 2014, 9, e110734.	1.1	20
31	Evaluation of a Tuberculosis Whole-Blood Interferon-Î³ Chemiluminescent Immunoassay among Chinese Military Recruits. Molecular Diagnosis and Therapy, 2011, 15, 341-346.	1.6	9
32	Latent tuberculosis infection among new recruits to the army in Beijing, China in 2009. Apmis, 2011, 119, 377-384.	0.9	9
33	Identification of Rifampin-Resistant Genotypes in Mycobacterium tuberculosis by PCR-Reverse Dot Blot Hybridization. Molecular Biotechnology, 2009, 41, 1-7.	1.3	8
34	Latent tuberculosis infection amongst new recruits to the Chinese army: Comparison of ELISPOT assay and tuberculin skin test. Clinica Chimica Acta, 2009, 405, 110-113.	0.5	18